This program will provide comprehensive overview of recent clinical trials and practical implications, case-based review of MR treatment options, and discussion of approaches for selecting appropriate surgical or transcatheter MR therapies.
This webcast provides comprehensive discussion of TAVR as continued progress is seen in patients with low surgical risk. Emphasis is placed on approaches to integrating quality of life (QOL) metrics into pre-procedural planning, and utilizing scores for effective quantification of long-term outcomes in low-risk TAVR patients.
This brief panel discussion touches upon expert-recommended approaches to such challenges- high case volume, patient education, care coordination- as well as other considerations for achieving excellence in heart team performance and patient outcomes in TAVR.
This enduring activity will discuss emerging clinical science pertaining to TAVR use in low-risk patient populations, considerations for integrating new TAVR knowledge into practice, and the shifting roles of transcatheter (TAVR) and surgical replacement (SAVR) as new clinical knowledge in these areas continues to emerge.
This program covers the essentials of adding TMVR, appropriate patient selection and screening, and optimal care. Gain the knowledge needed for these new therapies from expert faculty in an interactive program.
This program will look at the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Considerations for platelet inhibition before, during, and after PCI and the outcomes of establishing potent P2Y12 inhibition with medication will be discussed.
This webcast will provide panel discussion centered on critical analysis of ongoing clinical trials and emerging findings from the BIONYX trial (comparing outcomes of Resolute Onyx stent to the Orsiro stent).
This webcast will help interventional cardiologists and other members of the cardiac care team ensure that ASCVD patients receive optimal lipid-lowering therapy to reduce the risk of recurrent events.
This webcast will help clinicians develop a refined understanding of residual CVD risk in hypercholesterolemic patients and allow them to adjust prescribing behavior to reduce risk as much as possible.
